Cancer Advisor | One Day MD

Cancer Advisor · Precision Oncology Review ISSN (Online) pending  •  Volume 2, Issue 9  •  Narrative Review  •  Originally published: April 2026  •  Revised and updated: October 2026 DOI: pending  •  Cite as: Cancer Advisor Editorial Team. KRAS and RAS(ON) Inhibitors in 2026: Approved Therapies, Resistance Mechanisms, and the Pan-RAS Paradigm Shift. Cancer Advisor Precision Oncol Rev. 2026. Updated October 2026. Cancer Advisor Editorial Team | Medically reviewed and updated | About Us Abstract Background: KRAS, once considered an "undruggable" oncoprotein, is now targetable across multiple mutation subtypes and represents one of the most rapidly evolving areas of precision oncology, spanning non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). Objective: To synthesize the current (September 2026) regulatory status, pivotal trial evidence, resistance mecha...

White Paper · Integrative Oncology · June 2026 ✎ OneDayMD Editorial Team  Last Updated: September 2026   Medically Reviewed by: OneDayMD Editorial Team  DOI-equivalent: onedaymd.com/fenbendazole-cancer-protocol-2026 Abstract Background: Cancer remains the second leading cause of death globally. Advanced-stage disease carries poor prognosis, and a significant proportion of patients either fail conventional therapy or seek adjunctive options. Over the past decade, the repurposed antiparasitic agents fenbendazole, ivermectin, and mebendazole have attracted increasing attention for potential anti-neoplastic activity based on preclinical and emerging clinical data. Objective: To synthesise (1) a systematic case-series compilation of 760+ patient-reported outcomes across 31 cancer subtypes involving antiparasitic repurposed drugs; (2) an evidence-based 7-layer Metabolic Cancer Fram...